Cystic Fibrosis
Cystic fibrosis (CF) is an inherited multisystem disease that causes substantial clinical manifestations. It is caused by mutations in the CFTR gene and primarily affects the lungs, pancreas, liver, gastrointestinal tract and sweat glands. Understanding which anatomical structures are involved is essential for appreciating the complexity and progression of the disease¹.
Clinically Relevant Anatomy
CF causes production of thick, viscous mucus that obstructs exocrine glands and disrupts normal fluid and ion transport. The main anatomical structures affected include:
Bronchioles: obstructed by thick mucus that adheres to the airway walls.
Small intestine: may develop distal obstruction, including meconium ileus in newborns.
Pancreatic ducts: become obstructed, preventing normal secretion of digestive enzymes.
Bile ducts: may become obstructed and contribute to progressive liver injury.
Reproductive system:
Men: the vas deferens is often absent or obstructed.
Women: thickened cervical mucus can reduce fertility.
Musculoskeletal system:
Atrophy of respiratory musculature.
Atrophy and weakness of antigravity muscles such as gastrocnemius.
Kyphosis, which may contribute to neck and back pain¹.
Pathophysiology and Disease Mechanism
CF is a major cause of chronic suppurative lung disease in younger people of European ancestry. The central pathophysiological mechanism is impaired chloride transport due to CFTR dysfunction, which results in dehydrated airway surface liquid and ineffective mucociliary clearance. This promotes chronic inflammation, recurrent bacterial infection and gradual development of bronchiectasis and fibrotic lung injury².
Three central mechanisms are commonly described in relation to disease development²,³:
Reduced chloride secretion increases mucus viscosity and promotes bacterial colonization.
Increased reabsorption of sodium and water further dehydrates mucus and impairs airway function.
Obstruction of narrow ducts in affected organs leads to retention of secretions and infection.
In the airways, these changes cause mucus retention and infection. In the pancreas, obstruction prevents enzyme secretion and causes malabsorption. In the sweat glands, abnormal CFTR function results in high salt concentrations in sweat, which forms the basis of the sweat chloride test³.
Prevalence and Epidemiology
Prevalence varies between population groups:
White Americans: approximately 1 in 3,200
Black Americans: approximately 1 in 15,000
Hispanic/Latino Americans: approximately 1 in 9,200
Asian Americans: approximately 1 in 31,000⁴
Approximately 30,000 people in the United States and around 70,000 worldwide were reported to be living with CF in the cited sources⁴. In the United Kingdom, approximately 1 in 2,500 children is born with CF, with more than 9,000 people living with the diagnosis⁵. In Canada, incidence has been reported at around 1 in 3,600⁶. More than 40% of people with CF in the United States are now adults⁴.
Causes and Risk Factors
Cystic fibrosis is an autosomal recessive disorder caused by mutations in the CFTR gene. This gene encodes a chloride channel; when it is dysfunctional, salt and water transport across cell membranes is disturbed⁷. Disease develops only when a person inherits two pathogenic copies—one from each parent. A person who inherits one pathogenic copy is generally an asymptomatic carrier⁷.
There are several classes of CFTR mutation, and these can produce different levels of disease severity⁸.
Signs and Symptoms
Clinical presentation varies considerably between individuals and often begins in childhood. Some infants are symptomatic at birth, whereas others develop manifestations later in childhood. Common features include:
Persistent cough with thick mucus
Shortness of breath and expiratory wheeze
Frequent respiratory infections
Fatigue and weight loss
Salty-tasting skin
Meconium ileus in newborns
Bulky, greasy and foul-smelling stools
Poor weight gain and impaired growth
Muscle and joint pain
Affected Organ Systems
Lungs: Airway mucus is abnormally viscous and difficult to clear. Bacterial colonization develops, leading to infection and inflammation and, over time, obstructive and restrictive lung disease with hyperinflation and fibrosis⁹.
Pancreas: Mucus blocks pancreatic ducts so digestive enzymes do not reach the small intestine. This leads to malabsorption and weight loss. Stools are often greasy and foul smelling⁹.
Intestine: In newborns, CF may present with meconium ileus, bowel obstruction and failure to pass stool within 24–48 hours after birth. Children with CF may also develop chronic constipation and nutritional deficiency¹⁰.
Respiratory Manifestations
People with cystic fibrosis often present with a dry cough that may be recurrent or chronic. Over time, the cough frequently becomes productive with thick sputum. Other common features include dyspnea and chest pain, together with recurrent wheeze, pneumonia, pneumothorax and hemoptysis.
In infants and young children the most common features include:
Persistent diarrhea
Bulky, foul-smelling and fatty stools
Pale stools
Frequent respiratory infections or wheezing
Chronic cough with thick mucus
Salty-tasting skin
Poor weight gain and growth
Bowel obstruction (meconium ileus)
Abdominal distension, gas, vomiting and dehydration
In older children common features include:
Frequent respiratory infections
Fever, cough and dyspnea
Abdominal pain, flatulence and discomfort
Tachypnea and nasal flaring
Poor appetite and malnutrition
Delayed growth and development
Barrel-shaped chest
Genitourinary System
Infertility is a common consequence of CF. Men are frequently infertile because of congenital absence or obstruction of the vas deferens, whereas women may have reduced fertility because thick cervical mucus impedes sperm movement¹.
Musculoskeletal System
CF can also cause a range of musculoskeletal manifestations. Physiotherapists should be aware that patients may have reduced bone mineral density and thoracic hyperkyphosis, which can contribute to back pain. Muscle atrophy and myalgia are common, particularly in adults who have lived with CF for many years. Some patients may also develop osteoarthropathy, inflammatory arthritis and osteoporosis¹.
Other Medical Complications
Cystic fibrosis may also be associated with several other conditions, including:
Sinusitis and nasal polyps
Clubbing of the fingers and toes
Pneumothorax
Hemoptysis
Cor pulmonale
Rectal prolapse
Liver, pancreatic and gallbladder disease
Delayed puberty
Diagnosis
Diagnosis of cystic fibrosis is based on clinical history, examination and specific diagnostic investigations:
Sweat chloride test: Measures chloride concentration in sweat; elevated values support the diagnosis of CF.
Blood test or genetic analysis: Identifies pathogenic CFTR variants.
Chest X-ray and CT: Demonstrate structural changes and lung damage.
Pulmonary function testing: Assesses airflow limitation and overall lung function.
Sputum analysis: Identifies bacterial infection and colonization.
Stool testing: Assesses fat malabsorption and pancreatic function.
MRI: May be used in assessment of the lungs, heart, sinuses and gastrointestinal system.
Prognosis
Prognosis in CF depends largely on the severity of lung disease and timely intervention¹². CF is progressive and may ultimately lead to respiratory failure and/or cor pulmonale. Life expectancy has improved substantially over recent decades. A 2017 study reported median survival ages of 50.9 years in Canada and 40.6 years in the United States¹³. Factors associated with better prognosis include adequate nutrition and preserved pancreatic function¹⁴. Women have historically had poorer outcomes than men, and colonization with mucoid Pseudomonas aeruginosa, respiratory symptoms as the first manifestation, exposure to tobacco smoke and bronchial hyperresponsiveness are associated with poorer outcomes.
FEV₁ is one of the strongest predictors of survival and should be interpreted in relation to age and sex¹⁵.
Treatment and Management
Although there is no universal cure for CF, structured treatment and early intervention can substantially improve quality of life and survival. The role of physiotherapy has expanded from secretion drainage alone to a broad range of respiratory and musculoskeletal interventions.
Medical treatment includes:
Antibiotics for infections
Bronchodilators
Inhaled DNase to reduce mucus viscosity
Analgesic medication when required
Pancreatic enzyme replacement before meals, for example pancreatin
Vitamin and mineral supplementation
Vaccination, including influenza, pneumococcal and routine childhood vaccines¹⁶,¹⁷
Genetic and CFTR-Targeted Treatment: CF has been one of the most extensively studied genetic diseases in relation to gene therapy. The goal is to correct or compensate for the CFTR defect using vectors or other molecular approaches. Major challenges have included immune responses and limited delivery efficiency¹⁸.
In advanced cystic fibrosis lung disease, specific consensus guidelines address both common and uncommon complications in this patient group¹⁹.
Physiotherapy Management
The overall aims of physiotherapy in cystic fibrosis are to prevent secondary complications, optimize pulmonary function and promote quality of life. This includes effective airway-clearance techniques for mobilizing thick secretions and management of musculoskeletal problems when required²⁰.
Chest Physiotherapy
People with CF often require regular, systematic airway-clearance therapy. Important approaches include:
Postural drainage: Uses gravity-assisted positioning to facilitate drainage of secretions from specific lung regions and may also improve ventilation to less well-ventilated areas²⁰.
Percussion: Also known as chest clapping, in which rhythmic percussion is applied to the chest wall with a cupped hand over clothing or a towel to help loosen secretions²⁰.
Vibration and shaking: Rhythmic chest-wall pressure is applied during expiration to assist secretion mobilization²⁰.
Position changes and positioning: Supine, prone, side-lying or sitting positions may be used to facilitate secretion movement²⁰.
Supplemental oxygen may be required, particularly in more advanced disease.
Active Cycle of Breathing Techniques (ACBT)
ACBT is a commonly used airway-clearance approach combining three components²⁰:
Breathing control: Relaxed diaphragmatic breathing used for recovery and to reduce the risk of bronchospasm.
Thoracic expansion exercises: Deep inspirations with an inspiratory hold followed by relaxed expiration to expand the lungs and promote airflow behind secretions.
Forced Expiratory Technique (FET): Huffing—forced expiration through an open glottis—to move secretions from smaller toward larger airways²⁰.
PEP and Oscillating Techniques
PEP (Positive Expiratory Pressure): Resistance during expiration helps maintain airway patency and promotes airflow behind secretions. PEP can be delivered through a mask, mouthpiece or, in children, bubble PEP using tubing and water²⁰,²².
Oscillating PEP: Combines expiratory pressure with oscillation. Examples include Flutter, Cornet and Acapella, which provide varying resistance and vibration during expiration to help mobilize mucus²⁰.
Other Measures
Gentle huffing rather than forceful coughing may be recommended to reduce unnecessary airway compression.
Aerobic activity such as swimming, running and dancing can support secretion mobilization and improve cardiovascular fitness.
Parent education is essential. Parents are taught airway-clearance techniques, while older children and adults are progressively trained in self-management²³.
Airway Clearance and the Evidence Base
Although long-term comparative evidence is limited, airway-clearance therapy is widely recommended for established CF lung disease²⁴. No single technique has consistently been shown to be superior²⁶,²⁷, so patient preference, burden and adherence are important when selecting an approach²⁸,²⁹.
Routine airway-clearance therapy is time consuming and can be burdensome, making adherence a recurrent challenge²⁹,³⁰. Non-invasive ventilation may be used as an adjunct during airway clearance in moderate to severe disease and can also support gas exchange during sleep³².
The goal is to reduce inflammation, slow progression of bronchiectasis and prevent irreversible lung damage. Structural and inflammatory changes may already be present in apparently asymptomatic infants³³,³⁴. UK physiotherapists have therefore developed consensus-based recommendations for management of asymptomatic infants with CF³⁵.
Postural Drainage – Guidelines and Modifications
Head-down postural drainage has been questioned, particularly because of concern about gastroesophageal reflux in infants. This has contributed internationally to greater use of modified postural drainage without a head-down tilt³⁴. Many people with CF also produce relatively small volumes of sputum, so routine drainage positioning in the absence of substantial secretions has been debated³⁴.
A randomized crossover study reported that side-lying during inhalation therapy may improve regional pulmonary deposition of nebulized medication and therefore potentially improve treatment distribution³⁸.
Exercise and Physical Activity
Both short- and long-term benefits of regular physical activity are well established. For people with cystic fibrosis, exercise is a central component of physiotherapy and an important strategy for maintaining general health and reducing secondary complications. The specific benefit of inspiratory muscle training remains uncertain, but physical activity is encouraged in most contemporary recommendations²⁰.
Exercise programs can provide several benefits in CF, including improved physical fitness, assistance with airway clearance, delayed progression of exertional dyspnea and functional decline, maintenance of bone health, improved quality of life and better self-image²⁰.
Some literature suggests that exercise can complement traditional airway-clearance techniques and should be encouraged when clinically appropriate³⁹. Exercise may also influence ion transport and airway hydration, although the clinical significance of these mechanisms remains under investigation.
In a clinical study by Elbasan et al., children with CF and impaired lung function completed a six-week program combining active breathing techniques with treadmill aerobic exercise at 74–80% of maximal heart rate, three times per week for 30 minutes. Improvements were reported in physical fitness, thoracic mobility, muscle strength and endurance⁴⁰. A systematic review by Van Doorn included four randomized trials using aerobic, resistance and anaerobic training. Resistance training was associated with improved muscle strength, while aerobic and anaerobic training improved VO₂max, an important marker of exercise capacity and prognosis in CF⁴¹.
A randomized crossover study by Reix et al. compared traditional airway-clearance techniques with whole-body exercise combined with expiratory maneuvers. The exercise-based approach was considered an acceptable alternative and was well received by children with CF, partly because sessions could be varied to maintain motivation⁴².
Paranjape et al. examined an individualized home-based exercise program in children with CF. After two months, measures including the Modified Shuttle Walk Test, FEV₁, BMI and quality-of-life scores improved, with particularly notable changes in fitness and body image⁴³. Hoffman et al. also reported potential benefits of inspiratory muscle training in advanced lung disease⁴⁴, while a later study suggested that adults with CF can tolerate high-intensity interval training (HIIT) and may improve exercise endurance and functional capacity⁴⁵.
End-of-Life Care
Discussion of prognosis and the patient's preferences regarding treatment should begin before advanced disease develops. Many people with CF now reach adulthood, but severe progressive lung disease can still occur. Potential options, including lung transplantation, should be discussed early enough for the patient and family to consider benefits and burdens. When disease no longer responds to disease-directed treatment, palliative care should be available, including symptom-focused measures and, when appropriate, palliative sedation to relieve otherwise refractory suffering⁴⁶,⁴⁷.
Differential Diagnosis
CF can overlap clinically with several other conditions. Differentiation is based on the clinical pattern and targeted testing⁴⁸:
Primary ciliary dyskinesia: Usually not associated with pancreatic insufficiency, but chronic otitis media is common. Diagnosis may involve assessment of ciliary structure and function.
Primary immunodeficiency: Recurrent infections may occur together with low immunoglobulin levels. Immunological testing is required.
Asthma: Usually lacks chronic purulent bronchitis and digital clubbing. Diagnosis is based on clinical assessment and pulmonary function testing.
Gastroesophageal reflux disease (GERD): Does not cause pancreatic malabsorption. Swallowing or reflux assessment may be indicated.
Chronic aspiration: May resemble reflux-related respiratory disease but is not associated with pancreatic malabsorption. Swallow assessment may be required.
Celiac disease: Responds to a gluten-free diet and is diagnosed using serology and, when indicated, small-bowel biopsy.
Protein-losing enteropathy: Characterized by gastrointestinal loss of serum proteins and requires further gastrointestinal evaluation.
Outcome Measures
A range of outcome measures can be used when assessing and following patients with CF to evaluate function, respiratory capacity and quality of life⁴⁹:
Cystic Fibrosis Questionnaire-Revised (CFQ-R)
Cystic Fibrosis Questionnaire (CFQ)
Baseline and Transition Dyspnea Indexes (BDI-TDI)
FEV₁ and FVC, including their ratio
Blood-gas analysis and oxygen saturation
Sputum volume and auscultation
Computer-assisted analysis of respiratory sounds
VO₂max: An important indicator of exercise capacity and prognosis, usually expressed in ml/kg/min and suitable for repeated assessment over time³⁹.
Sources:
Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. 3rd ed. St.Louis: Saunders Elsevier; 2009. p788 – 799.
Mall M, Boucher RC. Pathogenesis of pulmonary disease in cystic fibrosis. In: Bush A, Alton EWF, Davies JC, Griesenback U, Jaffe A (Eds) Cystic Fibrosis in the 21st century Progress in Respiratory Research Karger, Basel 2006; 34:116-121
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373 (9678): 1891–904
Sheppard MN, Nicholson AG.The pathology of cystic fibrosis. Current Diagnostic Pathology. 2002; 8(1):50–59
Quinton PM. Cystic fibrosis: lessons from the sweat gland. Physiology. 2007;22(3):212-25.
Nhs.uk. Cystic fibrosis - NHS Choices, 2015. : http://www.nhs.uk/conditions/cystic-fibrosis/Pages/Introduction.aspx
Cysticfibrosis.ca. What is Cystic Fibrosis? - Cystic Fibrosis Canada. : http://www.cysticfibrosis.ca/about-cf/what-is-cystic-fibrosis/
Dodge J, Lewis P, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. European Respiratory Journal. 2007;29(3):522-526.
Sharma G. Cystic Fibrosis. Medscape. : https://emedicine.medscape.com/article/1001602-overview.
Hoffman LR, Ramsey BW. Cystic fibrosis therapeutics: the road ahead. Chest. 2013;143(1):207-13.
Goodman C, Snyder T. Differential Diagnosis for Physical Therapist Screening for Referral. 5th ed. St. Louis: Elsevier Saunders; 2013. p307.
Naehrig S, Chao CM, Naehrlich L. Cystic Fibrosis: Diagnosis and Treatment. Deutsches Ärzteblatt International. 2017;114(33-34):564.
Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med. 2017; 166:536–547
Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in Cystic Fibrosis. Journal of Cystic Fibrosis. 2017; 16:S70–S78.
Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, et al. Understanding the natural progression in% FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2012;67(10):860-6.
Somaraju UR, Solis-Moya A. Pancreatic enzyme replacement therapy for people with cystic fibrosis. Cochrane Database Syst. Rev. 2014;(10):CD008227.
Burgess L, Southern KW. Pneumococcal vaccines for children and adults with cystic fibrosis. Cochrane Database Syst Rev 2016;(9):CD008865
Wagner JA, Gardner P. Toward cystic fibrosis gene therapy. Annu Rev Med. 1997;48:203-16.
Kapnadak SG, Dimango E, Hadjiliadis D, Hempstead SE, Tallarico E, Pilewski JM, Faro A, Albright J, Benden C, Blair S, Dellon EP. Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis. 2020 Feb 27.
Prasad S, Orska T, Ferguson K, Agent P, Dodd M, Dhouibe E et al. Physiotherapy treatment in cystic fibrosis: airway clearance techniques [Internet]. 1st ed. Bromley: Cystic Fibrosis Trust; 2013 : http://www.cysticfibrosis.org.uk/media/151218/FS%20-%20Physiotherapy_airway%20clearance_v4_Apr_2013.pdf
enmurrcp. RT Chest Physiotherapy Demonstration. : http://www.youtube.com/watch?v=ErMTXJLE5es
Donadio MV, Campos NE, Vendrusculo FM, Stofella AM, da Silva Almeida AC, Ziegler B, Schivinski CI, Santuzzi CH, Sarges ED, Gonçalves FM, de Oliveira Ribeiro MÂ. Respiratory physical therapy techniques recommended for patients with cystic fibrosis treated in specialized centers. Brazilian Journal of Physical Therapy. 2019 Nov 29.
American Lung Association. Teach a child to belly breathe for relaxation: http://www.youtube.com/watch?v=VOnDA6_MAWI
van der Schans CP, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2000; (2): CD001401. DOI: 10.1002/14651858.CD001401
Flume PA, Robinson K, O’Sullivan B, Finder JD, Vender FL, Willey-Courand DB, et al. Cystic Fibrosis Pulmonary Guidelines: Airway Clearance therapies. Resp Care 2009;54(4):522-537
Main E, Prasad SA, van der Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. The Cochrane Database of Systematic Reviews 2005;(1): CD002011
Elkins M, Jones A, van der Schans CP. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2006;(2): CD003147
Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009;(1): CD006842
Pryor JA. A comparison of five airway clearance techniques in the treatment of people with cystic fibrosis. Thesis submitted for the degree of Doctor of Philosophy, Imperial College London 2005
Bucks RS, Hawkins K, Skinner TC, Horn S, Seddon P, Horne R. Adherence to Treatment in Adolescents with Cystic Fibrosis: The Role of Illness Perceptions and Treatment Beliefs. J Pediatr Psychol. 2009;34(8):893-902
Arias Llorente RP, Bousoño García C, Díaz Martín JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros. 2008;7(5):359-67
Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2007;(4):CD002769
Pryor JA, Main E, Agent P, Bradley JM. Physiotherapy. In: Bush A, Alton E, Griesenbach U, Jaffe A (Eds). Cystic Fibrosis in the 21st century. vol 34. London:Prog Respir Res. Basel, Karger; 2006. p301-308
Prasad AS. Annual Evidence Update on Cystic Fibrosis – Physiotherapy, NHS Evidence, 2009. :http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=311642
Association of Chartered Physiotherapists in Cystic Fibrosis, UK. Physiotherapy National Standards of Care for people with Cystic Fibrosis. 2009 :http://cms.interactivecsp.org.uk/uploads/documents/ACPCF%20National%20Standards%20of%20Care..doc
Lord of Phisiotherapy. Postural Drainage. : http://www.youtube.com/watch?v=TPZsP1ujg0U
Morrow BM. Airway clearance therapy in acute paediatric respiratory illness: A state-of-the-art review. South African Journal of Physiotherapy. 2019 Jun 25;75(1):12.
Dentice RL, Elkins MR, Verschuer J, Eberl S, Dwyer G, Bye PT. Side lying during nebulisation can significantly improve apical deposition in healthy adults and adults with mild cystic fibrosis lung disease: a randomised crossover trial. BMC pulmonary medicine. 2019 Dec 1;19(1):128.
Cerny F. Exercise and Cystic Fibrosis (CF) 2.0. Pediatric Exercise Science. 2013;25(4):616-23.
Elbasan B, Tunali N, Duzgun I, Ozcelik U. Effects of chest physiotherapy and aerobic exercise training on physical fitness in young children with cystic fibrosis. Italian Journal of Pediatrics. 2012; 38(2): 1-5.
van Doorn N. Exercise programs for children with cystic fibrosis: a systematic review of randomized controlled trials. Disability and Rehabilitation. 2010; 32(1): 41-49.
Reix P, Aubert F, Werck-Gallois MC, Toutain A, Mazzocchi C, Moreux N, et al. Exercise with incorporated expiratory maneuvers was as effective as breathing techniques for clearance with cystic fibrosis: a randomized crossover trial.J Physiother. 2012; 58(4): 241-47.
Paranjape S,Barnes LA, Carson KA, von Berg K, Loosen H, Mogayzel Jr, PJ. Exercise improves lung function and habitual activity in children with cystic fibrosis. Journal of Cystic Fibrosis. 2012; 11(1); 18-23.
Hoffman M, Augusto VM, Eduardo DS, Silveira BM, Lemos MD, Parreira VF. Inspiratory muscle training reduces dyspnea during activities of daily living and improves inspiratory muscle function and quality of life in patients with advanced lung disease. Physiotherapy theory and practice. 2019 Aug 21:1-1.
Sawyer A, Cavalheri V, Jenkins S, Wood J, Cecins N, Bear N, Singh B, Gucciardi D, Hill K. High-Intensity Interval Training Is Effective at Increasing Exercise Endurance Capacity and Is Well Tolerated by Adults with Cystic Fibrosis. Journal of clinical medicine. 2020 Oct;9(10):3098.
Sands D, Repetto T, Dupont LJ, Korzeniewska-Eksterowicz A, Catastini P, Madge S. End of life care for patients with cystic fibrosis. J Cyst Fibros. 2011;10(2):S37-44. doi: 10.1016/S1569-1993(11)60007-6.
Beers MH, Sharp M, Dohme Research Laboratories (Rahway NJ.). The Merck manual of geriatrics. Whitehouse Station, NJ : Merck Research Laboratories, 2006.
Epocrates. Cystic Fibrosis. : https://online.epocrates.com/u/2935403/Cystic+fibrosis/Diagnosis/Differential
Marques A, Bruton A, Barney A. Clinically useful outcome measures for physiotherapy airway clearance techniques: a review. : http://www.academia.edu/441672/Clinically_useful_outcome_measures_for_physiotherapy_airway_clearance_techniques_a_review
